共 28 条
[1]
Nauts HC(1946)The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research Cancer Res. 6 205-216
[2]
Swift WE(2015)Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol. 33 2780-2788
[3]
Coley BL(2016)Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy Clin Cancer Res. 22 1048-1054
[4]
Andtbacka RHI(2016)Skin tumor immunity: site does matter for antigen presentation by DCs Eur J Immunol. 46 543-546
[5]
Kaufman HL(2016)The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes Eur J Immunol. 46 609-618
[6]
Collichio F(2010)Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol. 17 718-730
[7]
Kohlhapp FJ(2010)Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver Hum Gene Ther. 21 1119-1128
[8]
Kaufman HL(2016)Examination of industry payments to radiation oncologists in 2014 using the Centers for Medicare and Medicaid Services open payments database Int J Radiat OncolBiol Phys. 94 19-26
[9]
Waithman J(2016)Recap: pattern of duplicate presentations at national hematology-oncology meetings: influence of the pharmaceutical industry J Oncol Pract. 12 252-253
[10]
Gebhardt T(2015)Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs J Clin Oncol. 33 100-106